|
|
 |
|
Viewing report
|
|
|
|
Epidemiology: Hepatocellular Cancer
Datamonitor, Dec 2010, Pages: 42
It is estimated that 88,300 incident cases of hepatocellular cancer will occur in the seven major markets in 2010. This number is forecast to rise by 3% to 90,800 by 2020. Annual incident hepatocellular cases will increase in the US (49%) and each of the five major EU markets (France, Germany, Italy, Spain, and the UK) (20-28%). However, Japan will see a 25% decrease.
Scope of the report:
- Gain insight to market potential including a robust 10-year epidemiology forecast of hepatocellular cancer incident cases.
- Understand the key epidemiologic risk factors associated with hepatocellular cancer.
Highlights
In 2008, liver cancer was the fifth most commonly diagnosed cancer among men (522,000 cases) and the seventh most commonly diagnosed cancer among women (225,000 cases) worldwide. It is the 17th most commonly diagnosed cancer in the developed world and the fifth most commonly diagnosed cancer in the developing world.
Hepatocelluar cancer is primarily due to hepatitis C infection, but also hepatitis B and alcohol. The hepatitis C epidemic began in the 1940s in Japan, driving the sharp increase in incident hepatocellular cancer cases that began in the 1970s and peaked in the 1990s in this market. The US and EU follow Japan by approximately 20 years in this trend.
Reasons to purchase:
- What are the most robust sources for hepatocellular cancer incidence data?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- What are the major risk factors for hepatocellular cancer that drive the trend in incident cases and how are they changing?
|
|
|
|
